Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

Mounjaro is regarded as a significant advancement in the treatment of both diabetes and obesity, with Eli Lilly noting that the drug activates both GIP (glucose-dependent insulinotropic ...

Eli Lilly LLY recently announced its plans ... data bodes well for Lilly and could help establish the drug as the new standard for obesity medications. On Wednesday, Lilly reported that a phase ...